The Pharmacogenetics CORE integrates molecular genetics into the design and execution of the drug administration and clinical trials of pharmacotherapies for cocaine and methamphetamine dependence. The CORE will provide DNA isolation and DNA genotyping of cocaine- or methamphetamine-dependent patients from ongoing and completed clinical pharmacotherapy trials. Genetic variants and copy number variants (CNVs) will be analyzed for significant associations with response to pharmacotherapeutic treatment regimes. DNA samples will be evaluated for associations of 1) single nucleotide polymorphisms (SNPs), 2) copy number variants (CNVs), and 3) insertion/deletion variants with response to pharmacotherapy. As indicated in our Preliminary Data, we have started the examination ofthe CNVs. Searches ofthe literature and of bioinformatic databases will be conducted to translate the findings about the genetic associations with pharmacological responses into human studies. Genes with significantly associated variants identified from the bioinformatic searches will then be used in prospective pharmacogenetic selection of patients for the matching of these patients to the most appropriate of many available potential anti-addiction medications for further placebo controlled testing in either human laboratory drug administration or clinical trial studies.
The Pharmacogentics CORE will allow us to understand the genetic components that may influence a person's response to pharmacotherapy. The results of this research should allow the tailoring of treatment to each individual person.
|Zhang, Xuefeng; Nielsen, David A; Domingo, Coreen B et al. (2018) Pharmacogenetics of Dopamine ?-Hydroxylase in cocaine dependence therapy with doxazosin. Addict Biol :|
|Patriquin, Michelle A; Hamon, Sara C; Harding, Mark J et al. (2017) Genetic moderation of cocaine subjective effects by variation in the TPH1, TPH2, and SLC6A4 serotonin genes. Psychiatr Genet 27:178-186|
|Mahoney, James J; Kalechstein, Ari D; De Marco, Anthony P et al. (2017) The relationship between premorbid IQ and neurocognitive functioning in individuals with cocaine use disorders. Neuropsychology 31:311-318|
|Azadeh, Shabnam; Hobbs, Brian P; Ma, Liangsuo et al. (2016) Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. Neuroimage 125:813-824|
|Li, Xiaofan; Shorter, Daryl; Kosten, Thomas R (2016) Buprenorphine Prescribing: To Expand or Not to Expand. J Psychiatr Pract 22:183-92|
|Ayanga, Daniel; Shorter, Daryl; Kosten, Thomas R (2016) Update on pharmacotherapy for treatment of opioid use disorder. Expert Opin Pharmacother 17:2307-2318|
|Cao, Bo; Bauer, Isabelle E; Sharma, Ajaykumar N et al. (2016) Reduced hippocampus volume and memory performance in bipolar disorder patients carrying the BDNF val66met met allele. J Affect Disord 198:198-205|
|Shorter, Daryl; Nielsen, David A; Hamon, Sara C et al. (2016) The ?-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Pharmacogenet Genomics 26:428-35|
|Ma, Liangsuo; Steinberg, Joel L; Cunningham, Kathryn A et al. (2015) Inhibitory behavioral control: A stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls. Neuroimage Clin 7:837-47|
|Shorter, Daryl; Domingo, Coreen B; Kosten, Thomas R (2015) Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy. Expert Opin Emerg Drugs 20:15-29|
Showing the most recent 10 out of 70 publications